62557-32-8

Basic information

• Product Name: ETHYL 2-(2-AMINOTHIAZOL-5-YL)ACETATE
• Synonyms: ethyl 2-(2-aMino-1,3-thiazol-5-yl)acetate;Ethyl 2-(2-aminothiazol-5-yl)acetate hydrochloride;Ethyl 2-(2-aminothiazol-5-yl)acetate HCl;2-Amino-5-thiazoleacetic Acid Ethyl Ester;"5-Thiazoleacetic acid, 2-amino-, ethyl ester ";CBI-BB ZERO/005611;CHEMBRDG-BB 4141811;ETHYL 2-(2-AMINOTHIAZOL-5-YL)ACETATE
• CAS NO: 62557-32-8
• Molecular Formula: C₇H₁₀N₂O₂S
• Molecular Weight: 186.23
• Product Categories: CHIRAL CHEMICALS
• Mol File: 62557-32-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 100-101 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
• Boiling Point: 318.5 °C at 760 mmHg
• Flash Point: 146.4 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0.00036mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-(2-AMINOTHIAZOL-5-YL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(2-AMINOTHIAZOL-5-YL)ACETATE(62557-32-8)
• EPA Substance Registry System: ETHYL 2-(2-AMINOTHIAZOL-5-YL)ACETATE(62557-32-8)

Safety Data

• Hazardous Substances Data: 62557-32-8(Hazardous Substances Data)

Usage

Description

Ethyl 2-(2-aminothiazol-5-yl)acetate is an organic compound that serves as a crucial intermediate in the synthesis of various chemical compounds, particularly thiazoloquinazoline derivatives. These derivatives have been found to possess potent and selective inhibitory effects on aurora A and B kinases, which are important targets in the development of therapeutic agents for various diseases.

Uses

Used in Pharmaceutical Industry:
Ethyl 2-(2-aminothiazol-5-yl)acetate is used as a key intermediate for the synthesis of thiazoloquinazoline derivatives, which are potent and selective inhibitors of aurora A and B kinases. These kinases play a significant role in cell division and are often dysregulated in various cancers, making them attractive targets for therapeutic intervention. The inhibition of these kinases by thiazoloquinazoline derivatives can potentially lead to the development of novel anticancer drugs.
Additionally, Ethyl 2-(2-aminothiazol-5-yl)acetate may also be utilized in the development of other therapeutic agents targeting different biological pathways, given its versatile chemical structure and potential for further functionalization. This makes it a valuable compound in the ongoing search for new and effective treatments for a wide range of diseases.

InChI:InChI=1/C7H10N2O2S/c1-2-11-6(10)3-5-4-9-7(8)12-5/h4H,2-3H2,1H3,(H2,8,9)

Upstream product

• 56580-46-2 3-bromo-4-oxobutyric acid ethyl ester 
• 17356-08-0 thiourea 
• 999-10-0 ethyl 4-hydroxybutanoate 
• 14794-31-1 ethyl 3-(chloroformyl)propionate 
• 5472-38-8 diethyl 2-formylbutanedioate 
• 10138-10-0 ethyl 4-oxobutanoate 

Downstream Products

• 312581-28-5 (2-amino-thiazol-5-yl)-acetic acid amide 
• 29676-72-0 2-chloro-4-thiazoleacetic acid 
• 385784-82-7 ethyl (2-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1,3-thiazol-5-yl)acetate 
• 385785-31-9 2-(2-amino-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide 
• 52454-66-7 2-(2-aminothiazol-5-yl)acetic acid 
• 1258411-88-9 C₁₃H₉F₄N₃O₂S 
• 1258411-29-8 C₁₉H₂₁FN₈OS 
• 1258411-92-5 C₁₄H₁₁ClF₃N₃O₂S 
• 1258411-94-7 C₁₂H₁₂ClN₃OS 
• 1258411-31-2 C₂₀H₂₃ClN₈OS 
• 1258411-32-3 C₂₃H₂₉ClN₈O₂S 

Relevant articles and documents

Synthetic method of aminothiazole compounds

The invention provides a synthetic method of aminothiazole compounds, and belongs to the technical field of medicine synthesis. The synthetic method comprises the following steps: step f, reacting a compound with a structure as shown in a formula (VI) with selenium dioxide to obtain a compound with a structure as shown in a formula (VII) and the like. The synthetic method of the aminothiazole compound is mainly used for synthesizing the aminothiazole compound, is easy to operate, simple in post-treatment, mild in reaction condition and high in final product yield.

2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists

PCT No. PCT/SE98/01240 Sec. 371 Date Sep. 30, 1998 Sec. 102(e) Date Sep. 30, 1998 PCT Filed Jun. 25, 1998 PCT Pub. No. WO99/02501 PCT Pub. Date Jan. 21, 1999The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.

Thiazolo[3,4-b]isoquinolines

Isoquinoline derivatives of the formula STR1 wherein the symbol A1 represents an isoquinol-8-yl, 3-methylisoquinol-8-yl, 3-hydroxymethylisoquinol-5-yl, 3-carboxymethylisoquinol-5-yl, quinol-5-yl, thienopyridyl, benzimidazolyl, thienyl or thiazolyl radical, a 4-(or 5-)carboxyalkylthiazol-2-yl radical in which the alkyl moiety is linear or branched and contains 1 to 4 carbon atoms, or a 1,3,4-thiadiazol-2-yl, pyrazolyl, imidazolyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, monocyclic heterocyclic rings within the definition of A1 being optionally substituted by a linear or branched alkyl radical containing 1 to 4 carbon atoms, in the (S) or (R,S) form or mixtures thereof, and salts thereof possess useful pharmocological properties, in particular antiviral activity.